About this trial
This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 years or older
Newly diagnosed multiple myeloma according to WHO 2022 criteria
Pretreatment at time of sample collection
Age 18 years or older
Disqualifiers
- Other active malignancies or autoimmune diseases
Severe renal impairment (serum creatinine > 3.0 mg/dL)
Active infection or inflammatory disease at sampling
Pregnancy or lactation
Trial population
Patients with multiple myeloma and healthy controls attending South Egypt Cancer Institute, Assiut University.
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Mean serum soluble BCMA level
Mean serum soluble B-cell maturation antigen (sBCMA) concentration measured by ELISA in ng/mL.
Secondary outcomes
Mean serum soluble BCMA in newly diagnosed multiple myeloma
Mean serum sBCMA level in newly diagnosed multiple myeloma patients.
Mean serum soluble BCMA in relapsed/refractory multiple myeloma
Mean serum sBCMA level in relapsed or refractory multiple myeloma patients.
Mean serum soluble BCMA in healthy controls
Mean serum sBCMA level in healthy control subjects.
Mean hemoglobin level
Mean hemoglobin concentration in g/d
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: